South San Francisco, CA, May 6, 2008 - Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, announced that it has selected CB 813, an improved, second-generation variant of human coagulation factor VIIa, as a development candidate for the treatment of acute bleeding in hemophilia patients. Read more»
South San Francisco, CA, January 7, 2008 - Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, today announced that it has entered into an exclusive worldwide research and license agreement with Centocor Research & Development, Inc. Read more»
South San Francisco, CA, February 1, 2007 – Catalyst Biosciences, Inc., today appointed Erik Wiberg as the company’s Chief Financial Officer. Mr. Wiberg brings a significant financial and business background in the life sciences sector especially in the areas of business development, M & A and finance. Read more»
South San Francisco, CA, January 7, 2007 – Catalyst Biosciences, Inc., today announced that it has signed two research collaboration and license agreements with Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), having potential total payments of up to $100 million, exclusive of potential royalty payments. Read more »
Press Coverage
- BioCentury - 1/15/07 (PDF - 668KB)
- BioWorld Today - 1/09/07 (PDF - 147KB)
- BioWorld Today - 2/09/06 (PDF - 142KB)
- Biotech Research Pioneer Appointed to UCSF Faculty - 6/28/05
- BioCentury - 1/17/05 (PDF- 631KB)
- BioWorld Today - 10/29/04 (PDF- 107KB)
- BioCentury - 1/26/04 (PDF - 511KB)
